NL1030405C2 - L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide. - Google Patents

L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide. Download PDF

Info

Publication number
NL1030405C2
NL1030405C2 NL1030405A NL1030405A NL1030405C2 NL 1030405 C2 NL1030405 C2 NL 1030405C2 NL 1030405 A NL1030405 A NL 1030405A NL 1030405 A NL1030405 A NL 1030405A NL 1030405 C2 NL1030405 C2 NL 1030405C2
Authority
NL
Netherlands
Prior art keywords
asthma
bronchitis
hydroxy
inhibitors
phenyl
Prior art date
Application number
NL1030405A
Other languages
English (en)
Dutch (nl)
Other versions
NL1030405A1 (nl
Inventor
Stefan Colin John Taylor
Kim James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NL1030405A1 publication Critical patent/NL1030405A1/nl
Application granted granted Critical
Publication of NL1030405C2 publication Critical patent/NL1030405C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL1030405A 2004-11-12 2005-11-11 L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide. NL1030405C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0425057A GB0425057D0 (en) 2004-11-12 2004-11-12 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
GB0425057 2004-11-12

Publications (2)

Publication Number Publication Date
NL1030405A1 NL1030405A1 (nl) 2006-05-15
NL1030405C2 true NL1030405C2 (nl) 2006-12-12

Family

ID=33523659

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1030405A NL1030405C2 (nl) 2004-11-12 2005-11-11 L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide.

Country Status (8)

Country Link
AR (1) AR055282A1 (fr)
GB (1) GB0425057D0 (fr)
GT (1) GT200500328A (fr)
NL (1) NL1030405C2 (fr)
PE (1) PE20061131A1 (fr)
TW (1) TW200630324A (fr)
UY (1) UY29207A1 (fr)
WO (1) WO2006051375A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2196465A1 (fr) 2008-12-15 2010-06-16 Almirall, S.A. Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
EP2394998A1 (fr) 2010-05-31 2011-12-14 Almirall, S.A. Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
EP1460064A1 (fr) * 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
EP1577291A1 (fr) * 2004-03-17 2005-09-21 Pfizer Limited Dérivés béta-2 agonistes de la phényléthanolamine

Also Published As

Publication number Publication date
GB0425057D0 (en) 2004-12-15
TW200630324A (en) 2006-09-01
WO2006051375A1 (fr) 2006-05-18
GT200500328A (es) 2006-06-02
AR055282A1 (es) 2007-08-15
NL1030405A1 (nl) 2006-05-15
UY29207A1 (es) 2006-06-30
PE20061131A1 (es) 2006-10-20

Similar Documents

Publication Publication Date Title
NL1030405C2 (nl) L-tartraatzout van N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxy- methyl)fenyl)ethyl}amino)propyl)fenyl}aceetamide.
JP4036343B2 (ja) 疾患の治療のためのスルフォンアミド誘導体
JP4490911B2 (ja) β−２アゴニストとしてのインドール誘導体
ES2291882T3 (es) Derivados de 2-(6-amino-piridin-3-il)-2-hidroxietilamina como agonistas de adrenoceptores beta 2.
NL1028087C2 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
NL1026327C2 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
NL1028599C2 (nl) Verbindingen voor de behandeling van ziekten.
JP2007529499A (ja) β２受容体アゴニストとしてのフェニルアミノエタノール誘導体
JP3966897B2 (ja) ベータ２アゴニストとしての（２−ヒドロキシ−２−（４−ヒドロキシ−３−ヒドロキシメチルフェニル）−エチルアミノ）−プロピル−フェニル誘導体
JP2010505810A (ja) アドレナリン作動薬およびムスカリン拮抗薬としてのスルホンアミド誘導体
WO2011163502A1 (fr) Dérivés d'acides cycloalkyl- et cycloalcényl-1,2-dicarboxyliques présentant une activité agoniste ou antagoniste du récepteur fprl-1
JP4054366B2 (ja) 疾患の治療のために有用な化合物
JP6013498B2 (ja) リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
EP1574501A1 (fr) Dérivés de quinoléinone, compositions pharmaceutiques les contenant et leur usage
JP4819770B2 (ja) アドレナリン受容体として有用なホルムアミド誘導体
KR100794844B1 (ko) 질병 치료용 설폰아마이드 유도체
US20060106107A1 (en) L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide
EP1407769A1 (fr) Derivés d'indole comme beta-2 agonistes
MXPA06010629A (en) Phenylaminoethanol derivates as beta2 receptor agonists
KR20070026425A (ko) 질환 치료용 화합물

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20060811

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20090601